Reviewed by Michael Gill, B. Sc.
Image of Retina Vitreous Associates Medical Group in Beverly Hills, United States.
Phase-Based Progress Estimates
3
Effectiveness
3
Safety

Ozurdex Armfor Macular Edema

18+
All Sexes
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema. Previous studies have shown that inflammatory mediators and growth factors, such as vascular endothelial growth factor (VEGF), are elevated in patients with macular edema associated with CRVO. Ozurdex® is approved by the Food and Drug Administration (FDA) and is available by prescription for macular edema following CRVO and branch retinal vein occlusion (BRVO). It is also indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. The approved dosage is 0.7 mg. Ranibizumab (Lucentis®) is approved by the Food and Drug Administration (FDA) and is available by prescription for other eye disorders, such as wet age-related macular degeneration (AMD), macular edema following CRVO or BRVO, and diabetic macular edema (DME). The approved dosage for wet AMD and macular edema following CRVO/BROV is 0.5 mg given monthly. The approved dosage for DME is 0.3 mg given monthly. Dr. Gonzalez is conducting an investigational study on the safety and effectiveness of treating CRVO-associated Macular Edema with a combination of 0.7 mg of Ozurdex® and 0.5 mg Lucentis®, given as separate injections into the eye.
Phase 4
Waitlist Available
Retina Vitreous Associates Medical Group (+4 Sites)VICTOR H. GONZALEZ, MD
11 Retinal Vein Occlusion Clinical Trials Near Me
Top Hospitals for Retinal Vein Occlusion Clinical Trials
Image of Retina Consultants of Texas in Texas.
Retina Consultants of Texas
Bellaire
3Active Trials
4All Time Trials for Retinal Vein Occlusion
2018First Retinal Vein Occlusion Trial
Image of Retinal Research Institute, LLC in Arizona.
Retinal Research Institute, LLC
Phoenix
3Active Trials
5All Time Trials for Retinal Vein Occlusion
2018First Retinal Vein Occlusion Trial
Top Cities for Retinal Vein Occlusion Clinical Trials
Image of Austin in Texas.
Austin
7Active Trials
Austin Retina AssociatesTop Active Site
Image of Springfield in Illinois.
Springfield
4Active Trials
Prairie Retina CenterTop Active Site
Retinal Vein Occlusion Clinical Trials by Phase of Trial
Phase < 1 Retinal Vein Occlusion Clinical Trials
1Active Retinal Vein Occlusion Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Retinal Vein Occlusion Clinical Trials by Age Group
Most Recent Retinal Vein Occlusion Clinical Trials
Top Treatments for Retinal Vein Occlusion Clinical Trials
Treatment Name
Active Retinal Vein Occlusion Clinical Trials
All Time Trials for Retinal Vein Occlusion
First Recorded Retinal Vein Occlusion Trial
Faricimab
2
2
2021
2 mg ANXV - active
1
1
2022
bevacizumab
1
4
2009
KSI-301
1
2
2018
Episcleral Celecoxib
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Retinal Vein Occlusion
Treatment
Year
Sponsor
MHU650
2020
Novartis Pharmaceuticals
Minocycline
2012
National Eye Institute (NEI)

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: October 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014 Dec 9;56(1):81-9. doi: 10.1167/iovs.14-15415. https://pubmed.ncbi.nlm.nih.gov/25491299